PL4036095T3 - Pochodne 4-fluoro-1H-pyrazolo[3,4-c]pirydyny jako selektywne inhibitory kinazy tyrozynowej Brutona (BTK) w leczeniu chłoniaka z komórek B i chorób autoimmunologicznych - Google Patents

Pochodne 4-fluoro-1H-pyrazolo[3,4-c]pirydyny jako selektywne inhibitory kinazy tyrozynowej Brutona (BTK) w leczeniu chłoniaka z komórek B i chorób autoimmunologicznych

Info

Publication number
PL4036095T3
PL4036095T3 PL20867917.5T PL20867917T PL4036095T3 PL 4036095 T3 PL4036095 T3 PL 4036095T3 PL 20867917 T PL20867917 T PL 20867917T PL 4036095 T3 PL4036095 T3 PL 4036095T3
Authority
PL
Poland
Prior art keywords
btk
pyrazolo
fluoro
inhibitors
treatment
Prior art date
Application number
PL20867917.5T
Other languages
English (en)
Inventor
Chunli SHEN
Xiawei WEI
Chengde Wu
Guoping Hu
Ning Jiang
Wei Zheng
Jian Li
Shuhui Chen
Original Assignee
Jumbo Drug Bank Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jumbo Drug Bank Co., Ltd. filed Critical Jumbo Drug Bank Co., Ltd.
Publication of PL4036095T3 publication Critical patent/PL4036095T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL20867917.5T 2019-09-26 2020-09-25 Pochodne 4-fluoro-1H-pyrazolo[3,4-c]pirydyny jako selektywne inhibitory kinazy tyrozynowej Brutona (BTK) w leczeniu chłoniaka z komórek B i chorób autoimmunologicznych PL4036095T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910919180 2019-09-26
CN202010330226 2020-04-24
PCT/CN2020/117690 WO2021057893A1 (zh) 2019-09-26 2020-09-25 作为选择性btk激酶抑制剂的吡唑并吡啶类化合物

Publications (1)

Publication Number Publication Date
PL4036095T3 true PL4036095T3 (pl) 2024-04-15

Family

ID=75164834

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20867917.5T PL4036095T3 (pl) 2019-09-26 2020-09-25 Pochodne 4-fluoro-1H-pyrazolo[3,4-c]pirydyny jako selektywne inhibitory kinazy tyrozynowej Brutona (BTK) w leczeniu chłoniaka z komórek B i chorób autoimmunologicznych

Country Status (20)

Country Link
US (1) US11739090B2 (pl)
EP (1) EP4036095B1 (pl)
JP (1) JP7213604B2 (pl)
KR (1) KR102500569B1 (pl)
CN (1) CN114450289B (pl)
AU (1) AU2020355845B2 (pl)
BR (1) BR112022005729A2 (pl)
CA (1) CA3152587C (pl)
DK (1) DK4036095T3 (pl)
ES (1) ES2972813T3 (pl)
FI (1) FI4036095T3 (pl)
HR (1) HRP20240283T1 (pl)
HU (1) HUE065965T2 (pl)
LT (1) LT4036095T (pl)
MX (1) MX2022003707A (pl)
PL (1) PL4036095T3 (pl)
PT (1) PT4036095T (pl)
RS (1) RS65239B1 (pl)
SI (1) SI4036095T1 (pl)
WO (1) WO2021057893A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3214116A1 (en) * 2021-03-23 2022-09-29 Jumbo Drug Bank Co., Ltd. A crystal form of a fluorine-substituted pyridopyrazole compound and a preparation method thereof
WO2024022234A1 (zh) * 2022-07-28 2024-02-01 成都嘉葆药银医药科技有限公司 吡唑并吡啶类化合物在制备治疗包括中枢神经系统疾病的btk相关疾病的药物中的用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2874756C (en) * 2007-03-28 2018-05-29 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US20150152115A1 (en) * 2007-12-27 2015-06-04 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
EP2470023A2 (en) 2009-08-27 2012-07-04 Polymers CRC Ltd. Nano silver-zinc oxide composition
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
CN103848810A (zh) * 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
WO2014113942A1 (en) * 2013-01-23 2014-07-31 Merck Sharp & Dohme Corp. Btk inhibitors
CA2915163A1 (en) * 2013-06-12 2014-12-18 Proximagen Limited New therapeutic uses of enzyme inhibitors
WO2015095099A1 (en) * 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Btk inhibitors
WO2015095102A1 (en) * 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Btk inhibitors
CN105017256A (zh) 2014-04-29 2015-11-04 浙江导明医药科技有限公司 多氟化合物作为布鲁顿酪氨酸激酶抑制剂
CN105085474B (zh) * 2014-05-07 2018-05-18 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
CN105399756B (zh) * 2014-09-05 2019-06-25 广东东阳光药业有限公司 Btk抑制剂及其用途
WO2016106652A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Biarylether imidazopyrazine btk inhibitors
WO2016106627A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Btk inhibitors
EP3313839A1 (en) 2015-06-24 2018-05-02 Principia Biopharma Inc. Tyrosine kinase inhibitors
CN105753863B (zh) * 2015-09-11 2018-07-31 东莞市真兴贝特医药技术有限公司 氧代二氢咪唑并吡啶类化合物及其应用
WO2017127371A1 (en) 2016-01-21 2017-07-27 Sunnylife Pharma Inc. Bruton's tyrosine kinase inhibitors
WO2017156495A1 (en) * 2016-03-11 2017-09-14 Corvus Pharmaceuticals, Inc. Compounds and methods for modulating bruton's tyrosine kinase
US11186578B2 (en) 2016-08-17 2021-11-30 Shenzhen Targetrx, Inc. Substituted pyrrolo[3,2-d]pyrimidines and pyrazolo[4,3-d]pyrimidines as tyrosine kinase inhibitors
JOP20190113A1 (ar) 2016-11-18 2019-05-15 Biocad Joint Stock Co مثبطات بروتون تيروزين كيناز
CN106588937B (zh) * 2017-01-16 2018-09-21 东莞市真兴贝特医药技术有限公司 咪唑并吡嗪类化合物及其制备方法和应用
CN110272416A (zh) * 2018-03-14 2019-09-24 武汉宇科源医药生物科技有限公司 吡唑并[3,4-c]吡啶-7-胺衍生物及其制备方法和应用

Also Published As

Publication number Publication date
SI4036095T1 (sl) 2024-04-30
CN114450289B (zh) 2024-01-02
PT4036095T (pt) 2024-02-19
ES2972813T3 (es) 2024-06-17
EP4036095B1 (en) 2024-01-31
LT4036095T (lt) 2024-03-25
AU2020355845B2 (en) 2023-04-06
KR20220061262A (ko) 2022-05-12
CN114450289A (zh) 2022-05-06
HUE065965T2 (hu) 2024-06-28
EP4036095A1 (en) 2022-08-03
AU2020355845A1 (en) 2022-05-19
MX2022003707A (es) 2022-06-23
JP7213604B2 (ja) 2023-01-27
FI4036095T3 (fi) 2024-02-14
US20220324864A1 (en) 2022-10-13
BR112022005729A2 (pt) 2022-06-21
WO2021057893A1 (zh) 2021-04-01
US11739090B2 (en) 2023-08-29
HRP20240283T1 (hr) 2024-05-10
CA3152587A1 (en) 2021-04-01
DK4036095T3 (da) 2024-03-04
CA3152587C (en) 2023-05-23
KR102500569B1 (ko) 2023-02-16
JP2022542196A (ja) 2022-09-29
EP4036095A4 (en) 2022-12-07
RS65239B1 (sr) 2024-03-29

Similar Documents

Publication Publication Date Title
TN2019000110A1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
MX2021015370A (es) Composiciones farmaceuticas de un inhibidor de tirosina cinasa de bruton.
HUE064667T2 (hu) Pirido[3',4':4,5]pirrolo[1,2,3-de]kinoxalin származékok központi idegrendszeri betegségek kezelésében történõ alkalmazásra
SG10201803331PA (en) Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
HK1258779A1 (zh) 用於治療癌症的作為btk抑制劑的吡唑並嘧啶衍生物
LT3880676T (lt) 2,3-dihidro-1h-pirolo[3,4-c]piridin-1-ono dariniai kaip hpk1 inhibitoriai, skirti vėžio gydymui
WO2010068483A3 (en) Mlk inhibitors and methods of use
ZA202203520B (en) [1,4]oxazepino[2,3-c]quinolinone derivatives as bcl6 inhibitors
GEP20247585B (en) Furoindazole derivatives
HK1249737A1 (zh) 布鲁顿氏酪氨酸激酶抑制剂的溶剂化形式
SG10201903619YA (en) Carbazole derivatives
SG10201810660QA (en) Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain
EP3709998B8 (en) N-[5-(imidazo[1,2-a]pyrimidin-2-yl)phenyl]-benzamide and -benzeneacetamide derivatives as tnf stimulators for the treatment of e.g. infectious diseases and cancer
EP3750891A4 (en) PYRAZOLO [1,5-A] [1,3,5] TRIAZINE-2-AMINE DERIVATIVE, METHOD OF PREPARATION AND MEDICAL USE
PL4036095T3 (pl) Pochodne 4-fluoro-1H-pyrazolo[3,4-c]pirydyny jako selektywne inhibitory kinazy tyrozynowej Brutona (BTK) w leczeniu chłoniaka z komórek B i chorób autoimmunologicznych
WO2018033941A3 (en) Pharmaceutical compositions of ibrutinib
MXPA05013200A (es) Derivados de estaurosporina para sindrome hipereosinofilico.
EP4051387C0 (en) HYDROPYRAZINO[1,2-D][1,4]DIAZEPINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE
HUE065093T2 (hu) 1,4-dihidrobenzo[D]pirazolo[3,4-F][1,3]diazepin származékok és kapcsolódó vegyületek, mint LRRK2, NUAK1 és/vagy TYK2 kináz modulátorok pl. autoimmun betegségek kezelésére
PH12019502620A1 (en) 6h-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative
MX383514B (es) Pirrolo[2,3-d]piridazin-4-onas sustituidas y pirazolo[3,4-d]piridazin-4-onas como inhibidores de la proteína quinasa.
MX2021014581A (es) Derivados heterociclicos condensados.
IL179040A0 (en) Methods of using and compositions comrpising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
HK40077345A (en) Tricyclic janus kinase (jak) inhibitors and their use in the treatment of autoimmune diseases
TW202610683A (zh) 艾薩妥昔單抗用於治療復發性和/或難治性多發性骨髓瘤的用途